USSTOCK.TODAY
Market Closed
Log in Sign up

Arrowhead Pharmaceuticals shares rise 6.7% on Alzheimer's treatment clinical data release

Investing.com +2 ·

ARWR
ARWR Arrowhead Pharmaceuticals Inc
$58.37 +0.41%
View chart & analysis →
  1. 1Arrowhead Pharmaceuticals shares rose 6.7% on Wednesday.
  2. 2The data showed an average 73% reduction in total tau protein in the cerebrospinal fluid of healthy volunteers through day 105.
  3. 3Investigators reported no serious adverse events, deaths, or instances of clinical discontinuation.

So what's the key point?

Arrowhead Pharmaceuticals' Alzheimer's treatment showed a 73% reduction in harmful proteins in the brain. The company's stock price rose because there were no reported side effects or deaths.

Source Investing.com +2 · View original ↗

Related 3-line summaries

Arrowhead Pharma target price raised on plozasiran clinical win; shares jump 19% Stocktwits +3 · Jul 24Arrowhead shares jump 18% on Phase 3 success of plozasiran InvestorsHub +1 · Jul 24Skydance Corporation shares fall following warrant allocation The Wall Street Journal +1 · 59m ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news